2014
Targeted agents: management of dermatologic toxicities.
Burtness B. Targeted agents: management of dermatologic toxicities. Journal Of The National Comprehensive Cancer Network 2014, 12: 793-6. PMID: 24853219, DOI: 10.6004/jnccn.2014.0192.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptor inhibitorsGrowth factor receptor inhibitorsDermatologic side effectsQuality of lifeDermatologic toxicitiesCutaneous complicationsSkin complicationsTherapeutic mainstayReceptor inhibitorsCommon culpritsToxicity profileMTOR inhibitorsSide effectsCosmetic issuesAnticancer treatmentPotential infectionComplicationsTreatmentInhibitorsTherapyAgentsCancerInfectionMainstayBRAF
2012
Predictors for response to cetuximab in a prospective clinical trial (E2303) of patients with head and neck squamous cell carcinoma (HNSCC).
Psyrri A, Lee J, Pectasides E, Vassilakopoulou M, Burtness B, Rimm D, Wanebo H, Forastiere A. Predictors for response to cetuximab in a prospective clinical trial (E2303) of patients with head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2012, 30: 5576-5576. DOI: 10.1200/jco.2012.30.15_suppl.5576.Peer-Reviewed Original ResearchClinical trialsEastern Cooperative Oncology Group Phase II TrialExact testStage III/IV HNSCCMultivariate Cox proportional hazards modelMultivariate Cox regression analysisERK1/2 levelsNeck squamous cell carcinomaCox proportional hazards modelEpidermal growth factor receptor inhibitorsPhase II clinical trialGrowth factor receptor inhibitorsManagement of HNSCCPhase II trialCox regression analysisKaplan-Meier methodProspective clinical trialsSquamous cell carcinomaLog-rank testAssociation of biomarkersProportional hazards modelFisher's exact testLogistic regression modelsProtein expression levelsWeekly cetuximab
2009
NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.
Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS, Myskowski PL, Paul J, Perlis CS, Saltz L, Spencer S. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. Journal Of The National Comprehensive Cancer Network 2009, 7 Suppl 1: s5-21; quiz s22-4. PMID: 19470276, DOI: 10.6004/jnccn.2009.0074.Peer-Reviewed Original ResearchConceptsTask force membersEGFR inhibitorsEpidermal growth factor receptor inhibitorsGrowth factor receptor inhibitorsNCCN Member InstitutionsOphthalmologic toxicityOncology providersOcular toxicityClinical trialsDifferent etiologiesReceptor inhibitorsEGFR inhibitionPatientsTask Force ReportTherapyToxicityInhibitorsSimilar toxicityTask ForceForce ReportReportExpert opinionOncologistsEtiologyOphthalmologists